Oragenics Aktie

Oragenics für 0 Euro bei ZERO ordern (zzgl. Spreads)

WKN DE: A2JBK2 / ISIN: US6840233026

<
Kurse + Charts + Realtime
Kurs + Chart
Times + Sales
Börsenplätze
>
<
News + Analysen
News + Adhoc
Analysen
Kursziele
>
<
Unternehmen
Termine
Profil
>
<
zugeh. Wertpapiere
Zertifikate
Optionsscheine
Knock-Outs
>
12.08.2024 15:07:53

Oragenics Successfully Completes Genotoxicity Study Of ONP-002 To Treat Concussion; Stock Up

(RTTNews) - Oragenics, Inc. (OGEN) Monday said its lead drug candidate ONP-002, proposed for the treatment of concussion, has successfully completed an in vivo study to determine if multi-day treatments of ONP-002 cause DNA damage and increased risk of cancer. The shares were up more than 6 percent in pre-market to $1.49.

A concussion is a mild traumatic brain injury that affects brain function.

Results from the in vivo study showed that multi-day treatment for concussion using ONP-002 will not cause genotoxicity. The company said it plans to conduct a Phase 2 study of ONP-002 in concussed patients.

Oragenics stock had closed at $1.40, up 29.63 percent on Friday. It has traded in the range of $0.86 - $7.74 in the last 1 year.

Nachrichten zu Oragenics Inc Registered Shsmehr Nachrichten

Keine Nachrichten verfügbar.

Analysen zu Oragenics Inc Registered Shsmehr Analysen

Eintrag hinzufügen
Hinweis: Sie möchten dieses Wertpapier günstig handeln? Sparen Sie sich unnötige Gebühren! Bei finanzen.net Brokerage handeln Sie Ihre Wertpapiere für nur 5 Euro Orderprovision* pro Trade? Hier informieren!
Es ist ein Fehler aufgetreten!